Insulin pumps in young children.
Insulin infusion pump therapy has dramatically improved over the past 20 years and can now address some of the specific challenges related to toddlers with diabetes. We discuss both the non-randomized and randomized controlled trials comparing continuous subcutaneous insulin infusion (CSII) and multiple daily injections (MDI) in this age group. There are advantages and disadvantages related to both CSII and MDI treatments, and ultimately the decision to use CSII should be individualized for each patient and family with the guidance of their diabetes team.
Fuld
Kimberly
K
Division of Pediatric Endocrinology and Diabetes, Stanford University School of Medicine, 300 Pasteur Drive, Stanford, CA 94305-5208, USA. kfuld@stanford.edu
Conrad
Barry
B
Buckingham
Bruce
B
Wilson
Darrell M
DM
D000293:Adolescent; D002675:Child, Preschool; D002986:Clinical Trials as Topic; D003922:Diabetes Mellitus, Type 1 / Q000097:blood / Q000188:drug therapy* / Q000453:epidemiology / Q000523:psychology; D005060:Europe / Q000453:epidemiology; D006442:Glycated Hemoglobin / Q000187:drug effects / Q000378:metabolism; D006801:Humans; D007003:Hypoglycemia / Q000517:prevention & control; D007004:Hypoglycemic Agents / Q000008:administration & dosage / Q000627:therapeutic use; D015994:Incidence; D007223:Infant; D007279:Injections, Subcutaneous / Q000009:adverse effects / Q000379:methods; D007328:Insulin / Q000008:administration & dosage / Q000627:therapeutic use; D007332:Insulin Infusion Systems; D010287:Parent-Child Relations; D011788:Quality of Life; D016032:Randomized Controlled Trials as Topic; D012201:Reward; D013315:Stress, Psychological
D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents; D007328:Insulin